Research tests for the diagnosis of tuberculosis infection
INTRODUCTION: Despite huge efforts, tuberculosis (TB) is still a major public health threat worldwide, it is estimated that a quarter of the global population is infected by Mycobacterium tuberculosis (Mtb). For controlling TB and reducing Mtb transmission it is fundamental to diagnose TB infection (TBI) as well as the progressors from TBI to disease to identify those requiring preventive therapy. At present, there is no gold standard test for TBI diagnosis although several new methodologies have been attempted.
AREAS COVERED: This review provides an update on the most recent approaches to develop reliable tests to diagnose TBI and progressors from infection to disease. Experimental tests are based on either the direct identification of Mtb (i.e., Mtb DNA upon host cells isolation; Mtb proteins or peptides) or host response (i.e., levels and quality of specific anti-Mtb antibodies; host blood transcriptome signatures).
EXPERT OPINION: The experimental tests described are very interesting. However, further investigation and randomized clinical trials are needed to improve the sensitivity and specificity of these new research-based tests. More reliable proofs-of-concept and simplification of technical procedures are necessary to develop new diagnostic tools for identifying TBI patients and those that will progress from infection to TB disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Expert review of molecular diagnostics - 23(2023), 9 vom: 01. Juli, Seite 783-795 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alonzi, Tonino [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Humoral response |
|---|
| Anmerkungen: |
Date Completed 27.10.2023 Date Revised 12.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14737159.2023.2240230 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360611915 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360611915 | ||
| 003 | DE-627 | ||
| 005 | 20231226083357.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14737159.2023.2240230 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360611915 | ||
| 035 | |a (NLM)37561602 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alonzi, Tonino |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Research tests for the diagnosis of tuberculosis infection |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2023 | ||
| 500 | |a Date Revised 12.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Despite huge efforts, tuberculosis (TB) is still a major public health threat worldwide, it is estimated that a quarter of the global population is infected by Mycobacterium tuberculosis (Mtb). For controlling TB and reducing Mtb transmission it is fundamental to diagnose TB infection (TBI) as well as the progressors from TBI to disease to identify those requiring preventive therapy. At present, there is no gold standard test for TBI diagnosis although several new methodologies have been attempted | ||
| 520 | |a AREAS COVERED: This review provides an update on the most recent approaches to develop reliable tests to diagnose TBI and progressors from infection to disease. Experimental tests are based on either the direct identification of Mtb (i.e., Mtb DNA upon host cells isolation; Mtb proteins or peptides) or host response (i.e., levels and quality of specific anti-Mtb antibodies; host blood transcriptome signatures) | ||
| 520 | |a EXPERT OPINION: The experimental tests described are very interesting. However, further investigation and randomized clinical trials are needed to improve the sensitivity and specificity of these new research-based tests. More reliable proofs-of-concept and simplification of technical procedures are necessary to develop new diagnostic tools for identifying TBI patients and those that will progress from infection to TB disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Humoral response | |
| 650 | 4 | |a IGRA | |
| 650 | 4 | |a Mtb DNA | |
| 650 | 4 | |a Mtb antigens | |
| 650 | 4 | |a TB progressors | |
| 650 | 4 | |a TBI diagnosis | |
| 650 | 4 | |a Transcriptome | |
| 650 | 4 | |a Tuberculosis | |
| 700 | 1 | |a Repele, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Goletti, Delia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of molecular diagnostics |d 2001 |g 23(2023), 9 vom: 01. Juli, Seite 783-795 |w (DE-627)NLM117852775 |x 1744-8352 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:9 |g day:01 |g month:07 |g pages:783-795 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14737159.2023.2240230 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 9 |b 01 |c 07 |h 783-795 | ||